Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051519 | 0.86 | KDM4E (0.54) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL12691127 | 0.85 | LMNA (0.50) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL17924042 | 0.82 | MAPT (0.59) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL4386263 | 0.81 | KDM4E (0.72) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27496748 | 0.79 | KDM4E (0.59) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL6750955 | 0.78 | KDM4E (0.58) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL6516869 | 0.78 | KDM4E (0.58) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL1878470 | 0.78 | KDM4E (0.58) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL21753772 | 0.78 | KDM4E (0.58) | KDM4ERAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL22772422 | 0.78 | KDM4E (0.58) | KDM4ERAB9AMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286986-B1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | EP | claimed |
| US-6753335-B2 | DELTA AGONISTS FOR NERVOUS SYSTEM PAIN | ASTRAZENECA AB (SE) | 2004-06-22 | — | — | US | claimed |
| US-20030199548-A1 | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | claimed |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| EP-4010328-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021023813-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-02-11 | — | — | WO | disclosed |
| CN-110248932-A | Pyrimidine tricycloalkenone derivatives for ROR γ inhibition and other uses | 里亚塔医药公司 | 2019-09-17 | — | — | CN | disclosed |
| US-9951272-B2 | Method of making semiconductor nanocrystals | SAMSUNG RESEARCH AMERICA, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9583715-B2 | Anthracene-based compounds and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-28 | — | — | US | disclosed |
| CN-106279101-A | Benzopyrazoles bipyridyliums compound, comprise the medical composition and its use of this compounds | 中国科学院上海药物研究所 | 2017-01-04 | — | — | CN | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-20030199548-A1 | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| EP-1286986-A1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2001074806-A1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | KDM4E 1380/4885RAB9A 3288/4885MAPT 3941/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | KDM4E 1105/4885RAB9A 2878/4885MAPT 3538/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | KDM4E 761/4885RAB9A 2456/4885MAPT 3386/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | KDM4E 1025/4885RAB9A 3018/4885MAPT 2881/4885 |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | KDM4E 3329/4885RAB9A 3738/4885MAPT 3231/4885 |
| US-20030199548-A1 | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain | OPRK1, OPRM1, OPRD1 | KDM4E 2698/4885RAB9A 2653/4885MAPT 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.